| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| ROMANO KATHRYN | Chief Accounting Officer | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH | /s/ Kathryn Romano | 11 Feb 2026 | 0001801385 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KRYS | Common Stock | Options Exercise | $794,375 | +12,500 | +65% | $63.55 | 31,818 | 09 Feb 2026 | Direct | F1 |
| transaction | KRYS | Common Stock | Sale | $541,116 | -2,000 | -6.3% | $270.56 | 29,818 | 09 Feb 2026 | Direct | F2 |
| transaction | KRYS | Common Stock | Sale | $1,548,477 | -5,700 | -19% | $271.66 | 24,118 | 09 Feb 2026 | Direct | F3 |
| transaction | KRYS | Common Stock | Sale | $769,562 | -2,824 | -12% | $272.51 | 21,294 | 09 Feb 2026 | Direct | F4 |
| transaction | KRYS | Common Stock | Sale | $254,001 | -928 | -4.4% | $273.71 | 20,366 | 09 Feb 2026 | Direct | F5 |
| transaction | KRYS | Common Stock | Sale | $151,601 | -552 | -2.7% | $274.64 | 19,814 | 09 Feb 2026 | Direct | F6 |
| transaction | KRYS | Common Stock | Sale | $110,272 | -400 | -2% | $275.68 | 19,414 | 09 Feb 2026 | Direct | F7 |
| transaction | KRYS | Common Stock | Sale | $26,676 | -96 | -0.49% | $277.88 | 19,318 | 09 Feb 2026 | Direct | F8 |
| transaction | KRYS | Common Stock | Gift | $0 | -750 | -3.9% | $0.000000 | 18,568 | 09 Feb 2026 | Direct | F9 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KRYS | Stock Option (Right to Buy) | Options Exercise | $0 | -12,500 | -50% | $0.000000 | 12,500 | 09 Feb 2026 | Common Stock | 12,500 | $63.55 | Direct | F1, F10 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on November 6, 2025, and will terminate on August 31, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. |
| F2 | The transaction was executed in multiple trades ranging from $270.010 to $270.950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F3 | The transaction was executed in multiple trades ranging from $271.105 to $272.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F4 | The transaction was executed in multiple trades ranging from $272.1275 to $273.070. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F5 | The transaction was executed in multiple trades ranging from $273.160 to $274.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F6 | The transaction was executed in multiple trades ranging from $274.305 to $274.815. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F7 | The transaction was executed in multiple trades ranging from $275.445 to $275.930. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F8 | The transaction was executed in a single trade. |
| F9 | Represents a bona fide gift of the Company's common stock to a charitable donor-advised fund. |
| F10 | The options vested ratably over a four-year period beginning on February 28, 2022. |